Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in advanced refractory biliary tract cancer
NCT03144856Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in biliary tract cancer (BTC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 1 year. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03144856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144856.